Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 to treat relapsed or refractory for non-hodgkin lymphoma (NHL) and chronic lymphocytic leukemia; ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL, as well as cemacabtagene ansegedleucel products as part of a first line treatment plan for newly diagnosed and treated large B cell lymphoma patients who are likely to relapse and need further therapy. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; joint research and collaboration agreement with AZ Ireland; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and investment agreement with AstraZeneca. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.